Comerica Bank reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.1% during the fourth quarter, Holdings Channel reports. The fund owned 41,152 shares of the life sciences company’s stock after selling 902 shares during the period. Comerica Bank’s holdings in Illumina were worth $6,690,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Sumitomo Mitsui Asset Management Company LTD boosted its position in Illumina by 1.2% in the second quarter. Sumitomo Mitsui Asset Management Company LTD now owns 11,158 shares of the life sciences company’s stock worth $1,566,000 after buying an additional 135 shares during the last quarter. Kornitzer Capital Management Inc. KS boosted its position in Illumina by 6.1% in the second quarter. Kornitzer Capital Management Inc. KS now owns 42,202 shares of the life sciences company’s stock worth $5,924,000 after buying an additional 2,430 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management boosted its position in Illumina by 18.7% in the second quarter. Gerber Kawasaki Wealth & Investment Management now owns 7,855 shares of the life sciences company’s stock worth $1,102,000 after buying an additional 1,238 shares during the last quarter. Concert Wealth Management Inc. boosted its position in Illumina by 6.6% in the second quarter. Concert Wealth Management Inc. now owns 1,684 shares of the life sciences company’s stock worth $236,000 after buying an additional 105 shares during the last quarter. Finally, RiverPark Advisors LLC bought a new position in Illumina during the second quarter worth $1,890,000. Hedge funds and other institutional investors own 92.79% of the company’s stock.
Illumina, Inc. (NASDAQ:ILMN) traded up 0.19% during midday trading on Tuesday, hitting $164.15. 188,236 shares of the stock traded hands. The company has a market cap of $24.10 billion, a price-to-earnings ratio of 53.47 and a beta of 0.79. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $186.88. The firm’s 50-day moving average is $153.95 and its 200-day moving average is $153.34.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, January 31st. The life sciences company reported $0.85 EPS for the quarter, topping the Zacks’ consensus estimate of $0.82 by $0.03. Illumina had a return on equity of 22.89% and a net margin of 19.31%. The business earned $619 million during the quarter, compared to the consensus estimate of $612.50 million. During the same period in the previous year, the company posted $0.81 earnings per share. The business’s revenue for the quarter was up 4.6% on a year-over-year basis. Analysts predict that Illumina, Inc. will post $3.63 EPS for the current year.
“Comerica Bank Has $6,690,000 Position in Illumina, Inc. (ILMN)” was first published by sleekmoney and is owned by of sleekmoney. If you are viewing this piece on another publication, it was illegally copied and reposted in violation of US & international copyright legislation. The correct version of this piece can be viewed at http://sleekmoney.com/comerica-bank-has-6690000-position-in-illumina-inc-ilmn/1660299.html.
A number of analysts recently commented on the stock. Zacks Investment Research cut shares of Illumina from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 19th. Vetr cut shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $154.48 price target on the stock. in a research note on Wednesday, October 19th. First Analysis cut shares of Illumina from an “equal weight” rating to an “underweight” rating and dropped their price target for the company from $130.00 to $116.00 in a research note on Wednesday, November 2nd. Canaccord Genuity set a $135.00 price target on shares of Illumina and gave the company a “hold” rating in a research note on Wednesday, November 2nd. Finally, BTIG Research restated a “hold” rating on shares of Illumina in a research note on Thursday, November 3rd. Three research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and nine have assigned a buy rating to the company. Illumina currently has an average rating of “Hold” and an average target price of $152.77.
In related news, Director Daniel Bradbury sold 600 shares of the business’s stock in a transaction that occurred on Monday, December 12th. The stock was sold at an average price of $123.42, for a total transaction of $74,052.00. Following the completion of the sale, the director now owns 17,065 shares in the company, valued at $2,106,162.30. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director A Blaine Bowman sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 8th. The stock was sold at an average price of $162.74, for a total value of $488,220.00. Following the sale, the director now owns 16,204 shares of the company’s stock, valued at approximately $2,637,038.96. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,525 shares of company stock valued at $2,682,340. Corporate insiders own 1.60% of the company’s stock.
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/comerica-bank-has-6690000-position-in-illumina-inc-ilmn/1660299.html
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.